

acceptable excipient, diluent or carrier.

48. (New) An antibody that binds specifically to the polypeptide of Claim 42.

49. (New) The antibody of Claim 48, wherein said antibody is a monoclonal antibody.

50. (New) The antibody of Claim 48, wherein said antibody is a polyclonal antibody.

51. (New) A formulation comprising the antibody of Claim 48 and a pharmacologically acceptable excipient, diluent or carrier.

52. (New) An isolated polypeptide having phosphatonin activity and being further characterized by:
regulating sodium dependent phosphate co-transport;
regulating renal 25-hydroxy vitamin D3-24-hydroxylase;
regulating renal 25-hydroxy-D-1-a-hydroxylase; and
regulating skeletal formation and/or mineralization.

53. (New) The polypeptide of Claim 52 having a molecular weight in a range of from about 53 to 60 kDa as measured on SDS-PAGE.

54. (New) The polypeptide of Claim 52 having a molecular weight of about 200 kDa as measured on a bis-tris SDS-PAGE at pH 7.

55. (New) The polypeptide of claim 52 comprising SEQ ID NO: 2.

56. (New) A formulation comprising the polypeptide of Claim 52 and a pharmacologically acceptable excipient, diluent or carrier.

57. (New) An antibody that binds specifically to the polypeptide of Claim 52.

58. (New) The antibody of Claim 57, wherein said antibody is a monoclonal antibody.

59. (New) The antibody of Claim 57, wherein said antibody is a polyclonal antibody.

60. (New) A formulation comprising the antibody of Claim 57 and a pharmacologically acceptable excipient, diluent or carrier.

61. (New) A polypeptide comprising an amino acid sequence of SEQ ID NO: 2.

62. (New) A formulation comprising the polypeptide of Claim 61 and a pharmacologically acceptable excipient, diluent or carrier.

63. (New) An antibody that binds specifically to the polypeptide of Claim 61.

64. (New) The antibody of Claim 63, wherein said antibody is a monoclonal antibody.

65. (New) The antibody of Claim 63, wherein said antibody is a polyclonal antibody.

66. (New) A formulation comprising the antibody of Claim 63 and a pharmacologically acceptable excipient, diluent or carrier.

REMARKS UNDER 37 CFR § 1.111

Formal Matters

Claims 42-66 are pending after entry of the amendments set forth herein.

Cancel claims 1-41 without prejudice with renewal, without intent to acquiesce to any rejection that may be applied thereon, and without the intent to abandon any subject matter encompassed therein.

New claims 42-66 are added.

No new matter has been added.